

Disclosures

Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Faraday Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Xenter	Stock	None (\$0)	<i>Invasive CV Angio and Interventions</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American College of Cardiology	Other - <i>Co-Editor Cath SAP</i>	Significant (>= \$5,000)	
American Heart Association	Other - <i>Senior Guest Editor, Circulation Intervention</i>	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
SCAI	Other - <i>On SCAI Education Council</i>	None (\$0)	

Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
REDUCE LAP-HF RANDOMIZED TRIAL II: A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure	Corvia medical Inc	
Medtronic Low Risk TAVR trial	MEDTRONIC	
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System in Patients at Low Risk for Surgical Aortic Valve Replacement.	MEDTRONIC	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (4)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2016	Delay in treatment	Defendant	Patient with acute stent thrombosis	Modest (< \$5,000)
2016	Failure to prescribe	Defendant	Stent thrombosis in patient who failed to fill prescription for DAPT	Modest (< \$5,000)
2015	Negligence	Defendant	Allegation of failure to provide timely revascularization in a STEMI patient with spontaneous coronary artery dissection	Significant (>= \$5,000)
2013	Malpractice	Defendant	Issue of failure to diagnose	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/21/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.